145 related articles for article (PubMed ID: 12027072)
1. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
[TBL] [Abstract][Full Text] [Related]
2. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
4. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
5. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells.
Kempuraj D; Huang M; Kandere-Grzybowska K; Basu S; Boucher W; Letourneau R; Athanassiou A; Theoharides TC
Int Arch Allergy Immunol; 2003 Nov; 132(3):231-9. PubMed ID: 14646384
[TBL] [Abstract][Full Text] [Related]
6. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.
Lytinas M; Kempuraj D; Huang M; Boucher W; Esposito P; Theoharides TC
Int Arch Allergy Immunol; 2003 Mar; 130(3):224-31. PubMed ID: 12660427
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells.
Matsubara M; Masaki S; Ohmori K; Karasawa A; Hasegawa K
Biochem Pharmacol; 2004 Apr; 67(7):1315-26. PubMed ID: 15013847
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
9. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
11. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
12. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
13. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
[TBL] [Abstract][Full Text] [Related]
14. Olopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformation.
Baba A; Tachi M; Maruyama Y; Kazama I
Cell Physiol Biochem; 2015; 35(1):386-96. PubMed ID: 25591779
[TBL] [Abstract][Full Text] [Related]
15. Ocular allergy treatment comparisons: azelastine and olopatadine.
Bielory L; Buddiga P; Bigelson S
Curr Allergy Asthma Rep; 2004 Jul; 4(4):320-5. PubMed ID: 15175148
[TBL] [Abstract][Full Text] [Related]
16. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells.
Kempuraj D; Madhappan B; Christodoulou S; Boucher W; Cao J; Papadopoulou N; Cetrulo CL; Theoharides TC
Br J Pharmacol; 2005 Aug; 145(7):934-44. PubMed ID: 15912140
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs.
Chand N; Pillar J; Diamantis W; Sofia RD
Agents Actions; 1985 Jul; 16(5):318-22. PubMed ID: 2413739
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
Lee JS; Lee JE; Kim N; Oum BS
J Ocul Pharmacol Ther; 2008 Dec; 24(6):557-62. PubMed ID: 19049267
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release.
He S; Aslam A; Gaça MD; He Y; Buckley MG; Hollenberg MD; Walls AF
J Pharmacol Exp Ther; 2004 Apr; 309(1):119-26. PubMed ID: 14722328
[TBL] [Abstract][Full Text] [Related]
20. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
